Welcome to our blog page. On this page we want to share our market access expertise build up over the past decades in the BeNeLux.
We wish you a lot of reading pleasure. If you have any questions or comments, you can always contact us.
How to prove the concerned price if the specialty is not yet produced? What is the value of a proven pricing structure if the price is downsized over time? Lets discuss to overcome this bottleneck.
You dive into a simulation model and at first everything seems flawless. But with each adjustment the risk of flaws creeping into the programming.
The 'ICER' is a well-known measure to assess the extra cost to invest to win one QALY. In Belgium, unofficially 35 000 € / QALY gained is often applied as benchmark, the 'willingness to pay' (WTP). But does the payer invest the budget in function of the potential medical need or not ?
How to prove the ‘added value’ when the concerned innovation is beneficial without producing ‘health’ in a direct way?
A model contains a large amount of inputs and every single input will be surrounded with uncertainty and the end result will be a translation of the composite effect of all inputs and their potential variance.
How to indicate if an innovation is worthwhile to pay for in view of the claimed benefit it will bring? The goal of the NMB is to compare two interventions by subtracting the NMB of ‘intervention A’ from the NMB of ‘intervention B’, resulting in the incremental NMB (iNMB).
